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ABSTRACT
RNA editing results in post-transcriptional modification and could potentially 
contribute to carcinogenesis. However, RNA editing in advanced lung adenocarcinomas 
has not yet been studied. Based on whole genome and transcriptome sequencing 
data, we identified 1,071,296 RNA editing events from matched normal, primary and 
metastatic samples contributed by 24 lung adenocarcinoma patients, with 91.3% 
A-to-G editing on average, and found significantly more RNA editing sites in tumors 
than in normal samples. To investigate cancer relevant editing events, we detected 
67,851 hyper-editing sites in primary and 50,480 hyper-editing sites in metastatic 
samples. 46 genes with hyper-editing in coding regions were found to result in amino 
acid alterations, while hundreds of hyper-editing events in non-coding regions could 
modulate splicing or gene expression, including genes related to tumor stage or 
clinic prognosis. Comparing RNA editome of primary and metastatic samples, we 
also discovered hyper-edited genes that may promote metastasis development. 
These findings showed a landscape of RNA editing in matched normal, primary and 
metastatic tissues of lung adenocarcinomas for the first time and provided new 
insights to understand the molecular characterization of this disease.
INTRODUCTION
Lung adenocarcinoma is a leading cause of 
cancerous deaths worldwide [1, 2] and great strides have 
been made to understand its molecular mechanism so 
that effective cure could be found [3–7]. Traditionally, 
mutations of the DNA sequence, especially those in cancer 
driver genes, have been heavily studied to understand the 
genetic basis of carcinogenesis. However, RNA editing, 
a post-transcriptional modification event that can flexibly 
and dynamically change RNA transcripts, could lead to 
effects similar to genomic mutations and potentially 
contribute to tumorigenesis as well. In mammals, 
RNA editing is mainly accomplished by the adenosine 
deaminase acting on RNA (ADAR) family of enzymes, 
which modifies adenosine to inosine (A -> I) [8, 9]. RNA 
editing is enriched in Alu elements [10], which overlaps 
with many introns and untranslated regions (UTRs) [11], 
Research Paper
Oncotarget11518www.impactjournals.com/oncotarget
and can modulate RNA structure, RNA splicing and 
transcript expression [12]. RNA editing has previously 
been associated with a few cancer types [12–17], such 
as hepatocellular carcinoma and prostate cancer. Pan-
cancer characterization of editing events, including 
lung adenocarcinoma, has also been carried out in two 
recent studies [18, 19] which found that RNA editing 
levels were significantly higher in lung adenocarcinomas 
than in paired normal tissues. Han et al. also found that 
ADAR1 expression levels exhibited significantly higher 
in lung adenocarcinomas than in normal samples, 
while ADAR2 expression levels were in the opposite 
direction [19]. Moreover, ADAR1 was reported to be 
an oncogene undergoing gene amplification-associated 
activation that affects downstream RNA editing patterns 
and patient prognosis in non-small-cell lung cancer 
cells [20]. Although most RNA editing in cancer were 
likely to be passenger events, a small portion may act as 
drivers and serve as potential markers for personalized 
diagnosis and therapy. For example, elevated editing of 
AZIN1S367G in hepatocellular carcinoma has been reported 
as oncogenic activity thus might be a potential driver in 
pathogenesis [13].
To our best knowledge, RNA editome of 
advanced lung adenocarcinomas, especially metastatic 
lung adenocarcinomas, has not been systematically 
characterized and the function of RNA editing in lung 
adenocarcinomas remains largely unknown. Here, we 
characterized the RNA editing landscape of the matched 
normal, primary and metastatic tissues from 24 lung 
adenocarcinoma patients based on whole genome and 
transcriptome sequencing and detected a large number 
of putative RNA editing events and hyper-editing 
sites, i.e., tumor-specific editing sites or editing sites 
with significantly higher editing levels in tumors than 
in adjacent normal samples. We also investigated the 
possible role of these events in primary and metastatic 
lung adenocarcinomas and provided new insights to 
understand the molecular characterization of this disease.
RESULTS
The landscape of RNA editing in 24 lung 
adenocarcinoma patients
The whole genome and transcriptome sequencing 
data of the adjacent normal, primary and corresponding 
lymph node metastatic tissues from 24 Chinese lung 
adenocarcinoma patients were obtained in a previous 
study [6]. The average depth of whole genome sequencing 
(WGS) is 31.9×, 49.6× and 51.2× for normal, primary and 
metastatic tissues, and the transcriptomes were sequenced 
to ~77M total reads per sample. We used an in-house RNA 
editing calling pipeline, which is an improved version of a 
previously published one [21], to identify 1,071,296 RNA 
editing sites (RES), with an average of 14,879 per sample 
(range from 800 to 43,708, Supplementary Table 1). As 
expected, the dominant editing type is A -> G, average 
91.3% in each sample (Figure 1A, Supplementary Figure 
1A, Supplementary Table 2), and the proportion of this 
editing type in primary samples were slightly higher than 
those in normal or metastatic samples (Supplementary 
Figure 1C). Most of the editing occurred in Alu regions 
(average 94.5%, range from 88.1% to 98.7%, Figure 1A, 
Supplementary Figure 1B and Supplementary Figure 1D, 
Supplementary Table 3). When looking at the distribution 
of RNA editing across different genomic regions, it most 
frequently occurred in introns (average 71.5% in each 
sample, range from 42.9% to 89.5%), followed by 3’ UTR 
(average 10.5%, range from 2.1% to 33.0%) and intergenic 
region (average 9.7%, ranger from 4.2% to 15.4%, Figure 
1A, Supplementary Figure 1B, Supplementary Table 3).
To account for sequencing and expression 
differences among samples, we calculated the editing 
rate (details in Method). The average editing rate is 121.2 
(range: 34.1 – 449.5) for normal samples, 190.4 (79.4 
– 473.3) for primary samples and 147.2 (62.0 – 448.5) 
for metastatic samples (Figure 1A, Supplementary Table 
1). Comparing the editing rates among the three groups, 
the editing rates in primary and metastatic samples are 
significantly higher than those in normal samples (P = 
3.26e-03 and P = 3.46e-02 respectively, Wilcoxon signed 
rank test). Moreover, the editing rates in primary samples 
are significantly higher than those in metastatic samples 
(P = 2.45e-02, Wilcoxon signed rank test). However, 
no correlation was found between the editing rate and 
clinical information of patients or the number of SNVs 
(as analyzed in the previous study, Supplementary Figure 
2) or tumor purity (average 0.54 in primary and 0.43 in 
metastatic samples, Supplementary Figure 3).
ADAR family of enzymes was found to be the 
primary modulator of the frequency and number of 
sites edited in some cancers [18, 19] and ADAR1/2 
dysregulation demonstrated extremely poor prognoses in 
non-small-cell lung cancer [20]. Therefore, we calculated 
the expression of ADAR family of enzymes to investigate 
the correlation with editing rate (Figure 1B). Compared 
to normal samples, ADAR1 was expressed significantly 
higher in primary and metastatic samples (P = 4.21e−02 
and P = 3.47e−03, paired t-test), while the opposite was 
found for ADAR2 and ADAR3 (P = 9.82e−11 and P = 
4.13e−08 in primary, P = 2.36e−10 and P = 1.02e−03 in 
metastatic, paired t-test). The higher expression levels of 
ADAR1, which was also reported in other solid tumors 
[19, 22–24], may explain why more RNA editing events 
occurred in tumor samples than in normal samples. 
However, there is no significant difference of ADAR1 
expression levels between primary and metastatic tumor 
samples, and the higher RNA editing rate in primary 
tumor samples could be partly due to the different tissue 
composition of primary and metastatic samples.
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Detection of hyper-editing events
To further investigate cancer relevant editing 
events, we detected hyper-editing sites (tumor-specific 
editing sites, which only edited in tumor but not in 
adjacent normal, or sites with significantly higher editing 
levels in tumor than adjacent normal from a patient). 
In total, we identified 67,851 hyper-editing sites in 
primary tumors (hyper-PT, Supplementary Table 4) and 
50,480 hyper-editing sites in metastatic tumors (hyper-
MT, Supplementary Table 6). These hyper-editing sites 
exhibited similar distribution to overall RES in terms 
of editing type and genomic regions (Supplementary 
Figure 4 versus Figure 1A, Supplementary Figure 5 and 
Supplementary Figure 6 versus Supplementary Figure 
1). To account for possible sequencing and expression 
differences among samples, we also calculated a hyper-
editing rate and found that hyper-editing rates of hyper-
PT (average 31.3) were significantly higher than those of 
hyper-MT (average 22.1, P = 2.29e-02, Wilcoxon signed 
rank test, Supplementary Figure 4) as well.
Figure 1: Summary of RNA editing events in adjacent normal, primary and metastatic samples from 24 patients. A. 
Circos plot depicting the landscape of RNA editing in lung adenocarcinoma. The outermost circle shows the samples for each patient and 
the numbers stand for the patient ID. Red, green and blue depict normal, primary and metastatic samples, respectively. The (i) and (ii) circle 
display the editing rate and the proportion of editing type for each sample, respectively. The (iii) and (iv) circle denote the distribution of 
editing sites in different genomic regions ((iii): intronic, UTR3, UTR5 etc; innermost: Alu and non-Alu). B. Comparison of ADAR family 
gene expression among adjacent normal, primary and metastatic samples. Red, green and blue points depict normal, primary and metastatic 
samples, respectively, and lines are drawn to connect samples from the same patient. **, P < 0.01; *, P < 0.05; measured by paired t-test.
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Hyper-editing in CDS regions
We first analyzed editing in CDS regions 
(including core splice sites), which may change the 
translated amino acid sequences. Altogether, we found 
213 hyper-PT and 328 hyper-MT in CDS regions. 
Comparing the number of hyper-PT and hyper-MT in 
CDS for the same patient, we found them to be similar 
for most patients, except three (patient ID 114, 212, 237, 
Figure 2A). Moreover, there was no obvious difference 
in the proportion of editing type and genomic distribution 
between hyper-PT and hyper-MT in CDS (Figure 2B, 2C 
and 2D). Owing to the lack of sufficient validation on 
non-A->G editing sites reported in previous studies [21, 
22], we only included A -> G hyper-PT and hyper-MT in 
subsequent analyses.
In total, we found 46 genes with hyper-editing 
had non-synonymous changes, including 20 genes with 
A -> G hyper-PT and 30 genes with A -> G hyper-MT 
(only 4 genes were shared, Supplementary Table 4, 
6 and 8, Supplementary Figure 7). Among them, the 
editing sites chr8:103841636 in AZIN1 (S367G) and 
chr4:2940026 in NOP14 (I779V), which were previously 
reported to have significantly elevated editing levels in 
lung adenocarcinoma from a pan-cancer analysis [19], 
were detected in two tumors and one tumor, respectively 
(Table 1). To investigate the role of non-synonymous A 
-> G hyper-editing, we further compared the proportion 
of cancer-related genes with non-synonymous A -> G 
hyper-editing to those with non-synonymous SNVs. We 
found 15.0% and 16.7% cancer-related genes with non-
synonymous hyper-editing in primary and metastatic 
samples (Table 1), while the proportion of cancer-related 
genes with non-synonymous SNVs is 6.1% and 5.9% 
(Figure 2E). This indicates that non-synonymous hyper-
editing may play as important a role as non-synonymous 
SNVs in lung adenocarcinoma, if not more.
Figure 2: Comparison of hyper-editing sites in CDS regions between primary and metastatic samples. A. The distribution 
of hyper-editing sites in CDS regions in each sample. B-D. Histograms showing the proportion of editing types (B), the proportion of Alu 
region (C) and the proportion of mutation types (D) of hyper-editing sites in CDS regions between primary and metastatic samples. E. The 
proportion of the cancer-related genes with non-synonymous A -> G hyper-editing sites or with non-synonymous SNV.
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Interestingly, we found that four cancer-related 
genes (CSF3R, MSH2, NUMA1 and KDM2A) only hyper-
edited in metastatic but not in primary samples (Table 1), 
suggesting that these alterations may promote metastasis 
development. Of which, CSF3R, which is a member of 
the family of cytokine receptors and may also function 
in some cell surface adhesion or recognition processes, 
was reported to be related to tumor growth and metastasis 
[25]. MSH2, a component of the post-replicative DNA 
mismatch repair system, frequently mutated in melanoma 
brain metastases but not in primary melanomas, indicating 
the high genomic instability of metastatic samples [26]. 
Moreover, MLH1/MSH2 defects were strongly associated 
with a decreased likelihood of lymph node and distant 
organ metastases in sporadic colorectal cancer [27]. To 
further investigate the role of non-synonymous hyper-
editing genes, we performed pathway enrichment analysis 
of these genes and found 3 genes (CSF3R, IL12RB1 and 
STAT2) in Jak-STAT signaling pathway only hyper-edited 
in metastatic but not in primary samples (Supplementary 
Figure 8, Supplementary Table 9). Activated Jak-STAT 
pathway could promote cellular invasion and migration 
in cancer, such as in hepatocellular carcinoma [28] and 
head and neck squamous cell carcinoma [29]. Some drugs 
have been reported to decrease proliferation and metastatic 
behavior of tumor cells by modulating Jak-STAT signaling 
pathway, such as guggulsterone for pancreatic cancer [30].
Hyper-editing in non-coding regions
In our samples, 95.7% of RNA editing took place 
in non-coding regions, especially introns and UTRs, 
where they could modulate splicing or RNA structure or 
gene expression. To investigate the potential correlation 
between editing and RNA splicing, we first used SPIDEX 
[31] to predict A -> G hyper-editing sites that may 
influence splicing. 20 A -> G hyper-PT and 16 A -> G 
hyper-MT were found, with 77.8% occurring in non-
coding regions (Supplementary Table 10, Supplementary 
Figure 7). Of which, HMOX2 (Heme Oxygenase 2), 
which belongs to the heme oxygenase family and is 
related to heme catabolism, was most frequently edited 
(detected in four primary and three metastatic samples) 
and harbored three hyper-editing sites (chr16: 4533677, 
4533713, 4533730, all located in 5’ UTR of exon3). To 
investigate the relationship between these three hyper-
editing sites and the splicing patterns of HMOX2 (Figure 
3A), we calculated the percent spliced in (PSI, detailed 
Table 1: The selected genes with non-synonymous A -> G hyper-editing
Gene Name Chr:Pos Editing type
Allele 
change
Amino 
acid 
change
Sample ID Class Description
AZIN1 chr8:103841636 A->G c.A1099G p.S367G 137F, 212G Reported Antizyme Inhibitor 1
NOP14 chr4:2940026 A->G c.A2335G p.I779V 212F Reported NOP14 nucleolar protein
CHD6 chr20:40127981 A->G c.A869G p.D290G 206F CRRG
Chromodomain 
helicase DNA 
binding protein 6
TCF3 chr19:1615370 A->G c.A1736G p.H579R 211F CGC Transcription factor 3
ATP1A1 chr1:116931630 A->G c.A743G p.N248S 114F, 114G CGC
ATPase, Na+/K+ 
transporting, alpha 1 
polypeptide
KDM2A chr11:67017933 A->G c.A1115G p.H372R 235G CRRG Lysine (K)-specific demethylase 2A
CSF3R chr1:36939477 A->G c.A373G p.I125V 128G CGC
Colony stimulating 
factor 3 receptor 
(granulocyte)
MSH2 chr2:47656925 A->G c.A1121G p.Q374R 212G CGC MutS Homolog 2
NUMA1 chr11:71725974 A->G c.A2575G p.I859V 210G CGC Nuclear mitotic apparatus protein 1
Note: Cancer Gene Census (CGC); Chromatin remodeling related genes (CRRG). “Reported” stands for gene has been 
previously reported. Cancer-related genes were found from GCG or TCGA driver genes list or CRRG list.
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in Method) of exon 3 in HMOX2. We found that the PSIs 
of tumor samples with at least one of three hyper-editing 
sites were significantly higher than those without them 
(P = 4.39e−02, Wilcoxon signed rank test, Figure 3B). 
Moreover, both the expression of exon3 and the transcript 
that contains exon3 (ENST00000458134) exhibited the 
same pattern (P = 3.24e−02 and P = 1.55e−02, Wilcoxon 
signed rank test, Figure 3C and 3D). In addition, we found 
a weak positive correlation between PSI and the editing 
index (see Method) of exon3 (Pearson correlation = 0.23, 
Figure 3E). These results suggested that hyper-editing in 5’ 
UTR of exon3 could increase the relative usage of exon3 
and the expression of the corresponding transcript, and the 
higher editing index of exon3, the greater the effect.
To further discover functional editing sites in non-
coding regions, we applied CADD [32] to predicted 
deleterious editing events. 32 A -> G hyper-editing events 
were predicted to be deleterious, including 14 hyper-PT 
and 18 hyper-MT, with 59.4% in non-coding regions 
(Supplementary Table 11, Supplementary Figure 7). Of 
which, chr17:8130348, located in the 3’ UTR of CTC1 
(CTS Telomere Maintenance Complex Component 1), is 
the most frequent deleterious hyper-editing site (detected 
in four primary and one metastatic samples). CTC1 is a 
component of the CST complex and this complex plays 
an essential role in protecting telomeres from degradation. 
To investigate the role of this event, we first compared 
the editing level of chr17:8130348 among three sample 
Figure 3: Hyper-editing induced splicing aberration of HMOX2. A. The average RNA-seq read coverage and junction counts 
are shown. Three red vertical lines in exon3 represent three A -> G hyper-editing sites (from left to right, 4533677, 4533713 and 4533730 
in chr16) predicted to affect splicing. Samples with the total number of the splice junction reads supporting J2, J3 and J4 less than 10 are 
excluded. B and C. Comparison of PSI (B) and expression of exon3 (C) in HMOX2 between two subgroups: tumor samples with at least one 
of the three hyper-editing sites in HMOX2 (“+”) versus those with none (“-”). Wilcoxon rank sum test was used. D. Box plot showing the 
expression levels of the corresponding transcript between “+” and “-” groups. P value was calculated by t-test. E. The correlation between 
the editing index of exon 3 and PSI. Pearson's product-moment correlation was used.
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groups, and found that the editing levels in tumor samples 
were significantly higher than those in normal samples (P 
= 6.18e−03 and P = 2.10e−02), while the editing levels in 
primary samples were also higher than metastatic samples 
(P = 4.90e−02, paired t-test, Figure 4A). Interestingly, the 
expression of CTC1 in primary samples were significantly 
lower than normal and metastatic samples (P = 2.44e−03 
and P = 6.35e−05, paired t-test, Figure 4B). Moreover, 
a negative correlation between the editing level of 
chr17:8130348 and the expression of CTC1 were found 
(Pearson correlation = -0.38, Figure 4C), which suggests 
possible regulation of decreasing CTC1 expression 
through RNA editing. Among cancer patients, those of 
early stage showed higher CTC1 expression than those 
of late stage (P = 3.51e−03, t-test, Figure 4D). Clinically, 
CTC1 down-regulation demonstrated poor recurrence-free 
survival probability (Log-rank P = 2.89e−02, Figure 4E). 
These results suggest that when deleterious hyper-editing 
do not alter amino acid sequences, they may affect gene 
expression and consequently promote tumor progression 
or influence clinical outcomes in lung adenocarcinoma.
As the above results showed, editing in UTRs, 
which contain binding sites for regulatory proteins and 
microRNAs, may induce differential gene expression 
in lung adenocarcinoma. To further investigate the 
association between hyper-editing events in UTRs and 
gene expression, we classified samples into two subgroups: 
edit+, which contains any A -> G hyper-editing sites in 
UTRs of a given gene; edit-, contrasting to edit+. Then 
we calculated the significance of differential expression 
between the samples of edit+ and edit- for each gene, 
requiring each group to have at least four samples. In total, 
we identified 39 and 30 genes having significant expression 
differences in primary and metastatic samples, respectively 
(using a threshold of P <= 0.05, t-test, Supplementary 
Table 12). Among the differentially expressed genes 
in primary samples, 7 of 39 genes (VHL, GNE, POLH, 
MAPK13, NOP14, INADL, CDC5L) were reported to be 
cancer-related in the literature (Supplementary Figure 9, 
Supplementary Table 13). Of which, VHL (Von Hippel-
Lindau syndrome) is a tumor suppressor and expressed 
significantly lower in edit+ primary samples than in edit- 
samples (P = 3.78e−02, t-test, Figure 5A). Abnormality of 
the VHL has been reported to be linked to the development 
of renal carcinomas [33, 34] and hemangioblastomas 
[35]. In addition, GNE (Glucosamine (UDP-N-Acetyl)-
Figure 4: Functional analysis of CTC1 with hyper-editing. A. The editing levels of the deleterious site (chr17:8130348) in CTC1 
among normal, primary and metastatic samples. B. The expression of CTC1 among three sample groups. C. The correlation between the 
editing level of chr17:8130348 and the expression of CTC1. D. CTC1 expression versus tumor stages (P value was calculated by the t-test). 
E. Kaplan-Meier survival curves showing the relationship between recurrence-free survival probability and CTC1 expression (low: less 
than median; high: greater than median).
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2-Epimerase/N-Acetylmannosamine Kinase) expressed 
significantly lower in edit+ primary samples than edit- 
samples (P = 2.81e−02, t test, Figure 5B). Clinically, 
we found patients with early stage showed higher GNE 
expression than those with late stage (P = 4.84e−02, 
t-test, Figure 5C). We also found patients with low GNE 
expression levels had poor recurrence-free survival 
probability (Log-rank P = 1.02e−02, Figure 5D). GNE 
dysregulation occurred predominantly in pancreatic 
cancer but also in other malignancies [36]. Among the 
differentially expressed genes in metastatic samples, we 
found 7 of 30 genes (MAPK13, XIAP, AHR, SPN, TER1, 
EMP2, NDUFC2) were cancer-related (Supplementary 
Figure 10, Supplementary Table 13). Of which, only one, 
MAPK13 (Mitogen-Activated Protein Kinase 13), was 
expressed significantly higher in both edit+ primary and 
metastatic samples than in corresponding edit- samples 
(Figure 5E, P = 3.3e−02 and P = 1.84e−02, t-test). 
MAPK13 is a component of the mitogen-activated protein 
(MAP) kinase family and plays an important role in the 
development of cancer, such as cholangiocarcinoma 
[37]. The remaining metastasis-specific genes could be 
related to metastasis development. Indeed, we found 
that XIAP (X-linked inhibitor of apoptosis), expressed 
significantly lower in edit+ than in edit- metastatic 
samples (P = 3.27e−02, t-test, Supplementary Figure 10), 
were reported to promote metastasis or tumor recurrence 
in hepatocellular carcinoma [38] and in papillary thyroid 
carcinoma [39], and AHR, expressed significantly higher 
in edit+ than in edit- metastatic samples (P = 5.7e−03, 
t-test, Supplementary Figure 10), were also reported 
to be associated with metastasis and may be a potential 
therapeutic target in the treatment of metastatic breast 
cancer [40].
DISCUSSION
The pathogenicity of advanced lung 
adenocarcinomas, especially metastatic lung 
adenocarcinomas, remains largely unknown and 
RNA editing is an important source of transcriptome 
diversification in cancer. This study represents a first 
systematic investigation and characterization of RNA 
editome in primary and metastatic lung adenocarcinomas 
Figure 5: Hyper-editing and differential gene expression. A. Differential expression of VHL between edit+ and edit- primary 
samples. B. Differential expression of GNE between edit+ and edit- primary samples. C. GNE expression versus tumor stages D. Kaplan-
Meier survival curves showing the relationship between recurrence-free survival probability and GNE expression. E. Differential expression 
of MAPK13 in edit+ and edit- groups for primary and metastatic samples. P values are calculated by t-test.
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based on matched whole genome and transcriptome 
sequencing data, where we identified 1,071,296 RES, 
67,851 hyper-PT and 50,480 hyper-MT sites. We found 
that editing events played a role in lung adenocarcinomas 
via changing amino acids, modulating alternative splicing 
patterns, such as in 5’ UTR of HMOX2, or affecting the 
expression of genes related to tumor stage and recurrence, 
such as in 3’ UTRs of CTC1 and GNE. Furthermore, 
by investigating hyper-edited genes only appeared in 
metastatic but not primary samples, we discovered genes 
and pathways that contribute to metastasis development, 
such as MSH2 and XIAP.
The role of editing events in cancer is still somewhat 
controversial and further investigations are warranted. 
One possible role of editing is to regulate alternative 
splicing. Alternative splicing and RNA editing, which are 
different post-transcriptional events, have the potential to 
generate many different mRNAs from the same gene, thus 
increasing the transcriptome and proteome diversity [41]. 
Editing could modulate alternative splicing by multiple 
means: creating the canonical 5’ and 3’ dinucleotide 
recognition sequences, destroying the 3’ recognition 
sequence or the internal branch point adenosine, targeting 
splicing enhancer or suppressor sequences [12]. Currently, 
little is known about this regulatory mechanism in cancer. 
A study identified that RNA editing can serve as a 
mechanism for regulating alternative splicing of ADAR2 
in rat [42]. Evidence also exists to indicate a relationship 
between TPH2 (Tryptophan hydroxylase 2) alternative 
splicing and RNA editing in psychiatric diseases [43]. In 
acute myeloid leukemia, editing in the putative branch 
site of tumor suppressor PTPN6 mRNA, which leads 
to aberrant intron retention, was suggested to account 
for PTPN6 functional insufficiency [44]. In this study, 
we also found that tumors with hyper-editing events in 
HMOX2 were related to the relative usage of exon and the 
expression of the corresponding transcript. Although there 
are no studies showing the relationship between HMOX2 
and cancer yet, HMOX1, a paralog of HMOX2, was known 
as a poor prognostic predictor and its over-expression 
may increase the metastatic potential of non-small cell 
lung cancer [45]. Interaction between RNA editing and 
alternative splicing, which can create a multitude of 
functionally distinct protein isoforms, might play a crucial 
role in tumorigenesis and joint analysis of both processes 
could be a new trend of cancer research.
RNA editing is dynamic and flexible and the editing 
levels may vary over time and tumor stages, which could 
be used to investigate cancer progress [19]. Recently, 
elevated editing of AZIN1 in hepatocellular carcinoma was 
reported to be related to tumor stages [13]. In this study, 
we compared RNA editome of primary and metastatic 
samples and found that RNA editing was significantly 
more frequent in primary than in paired metastatic 
samples. We also found a few genes affected by hyper-
editing could contribute to metastasis development. Future 
large-scale studies of lung adenocarcinoma samples with 
more tumor stages and more complete clinical information 
should help us to better understand the relationship 
between RNA editing and lung tumor progression. 
Ultimately, in-depth functional analysis of RNA editing 
in cancer will further our understanding of the molecular 
characteristic of this complex disease and may provide 
new insights for effective personalized therapies.
MATERIALS AND METHODS
Sequencing data
We obtained the BWA-aligned DNA sequencing 
data and RNA sequencing data (fastq files, Illumina 
sequencing) from the adjacent normal tissue, primary 
tumor and corresponding lymph node metastases tissue of 
24 Chinese lung adenocarcinoma patients in a previous 
study [6]. The method of sampling and sequencing were 
described in this previous study.
Data preprocessing and reads mapping
The raw reads of RNA sequencing data filtering 
process as follows: (1) Remove reads with sequence 
adaptors. (2) Remove reads in which unknown bases are 
more than 10%. (3) Remove low-quality reads, which 
have >50% in one read. Tophat2 were chose as the mapper 
for clean RNA-seq reads due to its high accuracy of 
alignment. After mapping reads to the reference genome 
(hg19), Picard (v1.84; http://broadinstitute.github.io/
picard/) and GATK (v2.8-1) software were used to remove 
identical reads (PCR duplicates) and recalibrate base 
quality, respectively.
In-house RNA editing sites calling pipeline
We used an in-house RNA editing sites calling 
pipeline, which is an improved version of a previously 
published one [21], to identify candidate editing sites. 
The basic principle for identifying an RNA-editing site is 
that the site must be homozygous for gDNA, while at the 
same time displaying a mismatch in RNA [46]. Firstly, We 
summarized the base calls of pre-processed aligned RNA-
reads to the human reference in pileup format. Secondly, 
the initially identified editing sits were then filtered by the 
following quality-aware steps: (1) The depth, base quality, 
mapping quality and the frequency of variation were taken 
into account to do a basic filtering. (2) Statistical test based 
on binomial distribution B(n, p) were used to distinguish 
true variants from sequencing errors on every mismatch 
site [46], where p denotes the background mismatch 
rate of each transcriptome sequencing, and n denotes 
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sequencing depth on this site. (3) Discard the sites present 
in dbsnp138. (4) Estimated strand bias and filtered out 
variants with strand bias based on two-tailed Fisher’s exact 
test. (5) Estimated and filtered out variants with position 
bias, such as sites at 3’-end or at 5’-end. (6) Discarded 
the variation site in simple repeat region or homopolymer 
region or splicing region. Finally, we summarized the 
candidate editing sites to DNA bam in pileup format, and 
only the site was homozygous in gDNA will be kept as a 
true editing site. Ultimately, all true editing sites were met 
minimal editing level of 10%, minimal edit bases of 3 and 
minimal depth of 4×.
Hyper-editing sites and hypo-editing sites calling
For each paired tumor-normal samples, hyper-
editing sites were detected in either case as follows. 1) 
Tumor-specific editing sites, which the sites only edited in 
tumor but not in adjacent normal from a patient. Namely, 
a given site only found in tumor samples with a minimal 
editing level of 10%, minimal edit bases of 3 and minimal 
depth of 6×, while paired normal samples were covered at 
least 6× without carrying any edit base. 2) The site showed 
significantly higher editing level in tumor than adjacent 
normal from a patient. The difference of editing level must 
be more than 0.2, and show significantly higher editing 
level in tumor than in adjacent normal samples (P <= 0.05, 
fisher test).
Similarly, hypo-editing site was found only in 
normal samples with a minimal editing level of 10%, 
minimal edit bases of 3 and minimal depth of 6×, while 
paired tumor samples were covered at least 6x without 
carrying any edit base. Or the difference of editing level 
must be less than -0.2, and show significantly higher 
editing level in normal than in tumor samples (P <= 
0.05, fisher test). The function of hypo-editing sites 
(Supplementary Table 5 and Supplementary Table 7) 
were not well known and those sites were ignored in this 
paper.
Definition
Editing rate is calculated as the total number of 
editing sites divided by the total length of transcriptome 
sequencing (minimal covered depth >=4, in Mega base) 
for a sample. Hyper-editing rate is defined to be the total 
number of hyper-editing sites divided by the total length 
of transcriptome sequencing, while hypo-editing rate 
was calculated as the total number of hypo-editing sites 
divided by the total length of transcriptome sequencing.
Editing level of a given editing sites is calculated 
as the variant-supporting reads divided by the total reads. 
For each paired tumor-normal samples, the difference in 
editing level of a given site for a patient is defined to be 
the editing level of this site in tumor sample minus the 
editing level in normal sample.
Gene expression and different expression
RPKM (reads per kilobase per million mapped 
reads) was used to calculate the gene expression and the 
formula is shown as follows:
= C
NL
RPKM  10
/ 10
6
3
In which, C is the number of uniquely mapping 
reads to a given gene, N is the total number of reads that 
are uniquely aligned to all genes and L stands for the total 
length of exons from the given gene.
To measure change in the expression level of a gene, 
different expression of a given gene was calculated as the 
log (fold change), and the formula is shown as follows:
)( = RPKMRPKMlog  fold change log ( )tumornormal2
Of which, RPKMtumor  stands for the RPKM of a 
given gene in tumor sample and RPKMnormal is the RPKM 
of this gene in normal sample.
Correlation between editing level and expression 
of gene
For a given editing site, Pearson's product-moment 
correlation was used to calculated the correlation between 
editing level and expression of gene. Samples with 
covered reads lower than 4 and the editing level equal to 
zero were excluded from this analysis.
Editing-induced splicing aberration
We used SPIDEX [31], which a comprehensive set 
of mutations and their predicted effects on RNA splicing 
across the entire human genome, to predict the editing 
sites with effects on splicing. The dataset was downloaded 
from the website (http://www.deepgenomics.com/spidex-
noncommercial-download). We selected the editing sites 
with the Z-score >= 2 or Z-score <= -2, which were 
predicted to more higher effect on splicing regulation.
Analysis of splice variants, the splice junction 
counts of HMOX2 and the FPKM of exon bins can be 
performed by SGSeq software package (v1.4.3) available 
from Bioconductor. We predicted exons and splice 
junctions from RNA BAM files for given genes using 
parameters alpha = 1, psi = 0, beta = 0.2, gamma = 0.2.
The percent spliced in (PSI) of HMOX2 was 
calculated by the formula as follows:
=
+
+
+
J J
J J J
PSI   
( 2 4)
2
( 2 4)
2
 3
Oncotarget11527www.impactjournals.com/oncotarget
In which, J2 is the splice junction counts of the 
junction between exon 2 and exon 3 of HMOX2. J3 stands 
for the splice junction counts of the junction between 
exon 2 and exon 7. J4 is the splice junction counts of the 
junction between exon 3 and exon 7 of this gene.
The editing index of exon 3 in HMOX2 measures 
the averaged editing level across exon 3 region, weighted 
by their expression. It may be quantified by the ratio of 
the read number of A-to-G/C/T editing sites with effects 
on splicing to the total number of reads—nucleotides 
aligned to a genomic adenosine within exon 3 region. Sites 
with covered reads lower than 4 were excluded from this 
analysis.
The deleterious editing sites
Combined Annotation Dependent Depletion 
(CADD, versions 1.3) is a tool for scoring the 
deleteriousness of single nucleotide variants in the human 
genome based on integrating multiple annotations into 
one metric by contrasting variants that survived natural 
selection with simulated mutations [32]. The CADD 
scores data can be downloaded from the website (http://
cadd.gs.washington.edu/download). In our work, the 
editing sites with the PHRED-like scaled C-score >= 
20, indicated that these sites are predicted to be the 1% 
most deleterious substitutions, were detected to be the 
deleterious editing sites.
Cancer-related genes list
Cancer-related genes can be found from GCG 
(Cancer Gene Census) genes list or TCGA driver genes 
list or chromatin remodeling related genes list. CGC genes 
[47] can be found in the website (http://cancer.sanger.
ac.uk/census) and the TCGA pan-cancer driver genes were 
found in dataset of a previous paper [48]. All chromatin 
remodeling related genes were found in three databases: 
HIstome (The Histone Infobase, http://www.actrec.gov.
in/histome/), EpiFactors (http://epifactors.autosome.ru/) 
and CREMOFAC (Chromatin Remodeling Factors, http://
www.jncasr.ac.in/cremofac/menuframe.html) database.
Pathway enrichment analysis
Editing genes were use to KEGG pathway 
enrichment analysis by GSEA database (http://www.
broadinstitute.org/gsea/index.jsp). Pathways, which the 
FDR (False discovery rate) q-value was below 0.05, 
were selected. To further investigate the role of non-
synonymous hyper-editing genes, we performed pathway 
enrichment analysis of these genes. Two pathways were 
enriched in metastatic samples, while no pathway enriched 
in primary samples.
Survival analysis and clinical association analysis
According to the median, we classified 56 primary 
tumors (including additional 32 primary tumor in 
Wu et al. paper, the transcriptome data by Ion Proton 
sequencing) into two groups: high expression level 
(greater than median) and low expression level (less than 
median). Kaplan-Meier survival analysis using R package 
“survival” (http://cran.r-project.org/web/packages/
survival/index.html). Log-rank test was used to compare 
the survival distribution of the above two subgroups.
To analyze the correlation between the expression 
of a given gene and clinical information, gender, smoking 
status, age and tumor stages were take into account. T test 
were used.
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